How TEVA’s Generic Medicines Franchise Is Positioned after 1H17

In 1H17, Teva Pharmaceutical Industries’ (TEVA) generic medicines business generated revenues of ~$6.1 billion, or ~22% higher YoY (year-over-year). In 2Q17, this business generated revenues of ~$3.1 billion, or ~20% higher YoY and 1% higher QoQ (quarter-over-quarter).

In 1H17, TEVA’s OTC (over-the-counter) products generated revenues of $547 million, or ~2% lower YoY. In 2Q17, OTC products reported revenues of ~$283 million, or ~6% higher YoY and 7% higher QoQ.

In 1H17, TEVA’s API (active pharmaceutical ingredients) products reported revenues of ~$401 million, or ~1% lower YoY. In 2Q17, API products generated revenues of ~$204 million, or ~1% lower YoY but ~4% higher QoQ.

In 2Q17, in the US, TEVA’s generic medicines business generated revenues of ~$1.3 billion, compared with ~$892 million in 2Q16. In US and European markets, generic medicines generated revenues of ~$957 million and $831 million, respectively, compared with $771 million and $897 million in 2Q16.

In 1H17, in the US, generic medicines generated revenues of ~$2.7 billion, compared with ~$1.9 billion in 1H16. In US and European markets, generic medicines generated revenues of ~$1.9 billion and $1.5 billion, respectively, compared with $1.56 billion and $1.59 billion in 2Q16.

TEVA’s peers include Novartis (NVS) (through Sandoz), Pfizer (PFE) (through Hospira), Sun Pharmaceuticals, GlaxoSmithKline, and Mylan (MYL). Notably, the PowerShares International Dividend Achievers Portfolio (PID) has ~0.87% of its total portfolio holdings in TEVA.